| Literature DB >> 34726310 |
Melgious Jin Yan Ang1,2,3, Jeehyun Yoon4,5, Mingzhu Zhou6, Han-Lin Wei6, Yi Yiing Goh1,2,3, Zhenglin Li1, Jia Feng4, Haifang Wang6, Qianqian Su6, Derrick Sek Tong Ong4,5,7,8, Xiaogang Liu1,2,3.
Abstract
Nanoparticles have been explored in glioblastomas as they can traverse the blood-brain barrier and target glioblastoma selectively. However, direct observation of nanoparticle trafficking into glioblastoma cells and their underlying intracellular fate after systemic administration remains uncharacterized. Here, based on high-resolution transmission electron microscopy experiments of an intracranial glioblastoma model, it is shown that ligand-modified nanoparticles can traverse the blood-brain barrier, endocytose into the lysosomes of glioblastoma cells, and undergo endolysosomal escape upon photochemical ionization. Moreover, an optimal dose of metronomic chemotherapy using dual-drug-loaded nanocarriers can induce an augmented antitumor effect directly on tumors, which has not been recognized in previous studies. Metronomic chemotherapy enhances antitumor effects 3.5-fold compared with the standard chemotherapy regimen using the same accumulative dose in vivo. This study provides a conceptual framework that can be used to develop metronomic nanoparticle regimens as a safe and viable therapeutic strategy for treating glioblastomas and other advanced-stage solid tumors.Entities:
Keywords: anti-angiogenesis; anti-glioma effect; blood-brain barrier; glioblastoma; metronomic chemotherapy; nanoparticles
Mesh:
Year: 2021 PMID: 34726310 DOI: 10.1002/adma.202106194
Source DB: PubMed Journal: Adv Mater ISSN: 0935-9648 Impact factor: 30.849